The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Prokineticin 2 and Prokineticin Receptor 2 as a Target to Treat Epilepsy and Seizures


Stanford Reference:

07-363


Abstract


PK2 belongs to a family of secreted peptides that regulate diverse biological functions including serving as a regulatory molecule for circadian rhythms. The signaling of PK2 is mediated through two cognate G-protein coupled receptors Prokineticin Receptor 1 and Prokineticin Receptor 2 (PKR1 and PKR2).

Researchers at Stanford and the University of California have found that PK2 is an important regulator of seizure onset and epilepsy. A PKR2 modulator would thus help treat epileptic patients and/or patients suffering from non-epileptic seizures. Certain materials such as cDNAs and cell lines that may be used as screening and research tools are readily available for licensing. This technology is also available for sponsor research opportunities.

Innovators & Portfolio


  • Michelle Cheng   
  • Robert Sapolsky   
  • Qun-Yong Zhou   

Patent Status



Date Released

 10/13/2010
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

04-237 Promoting myelination with gamma-secretase inhibitors
07-095 Role of extracellular matrix proteins Hevin and SPARC in Central Nervous System Synapse Formation
07-118 Small molecule drugs with TGFbeta signaling activity

more technologies

Related Keywords


CNS disorders   therapeutic: CNS   07-363   
 

   

  

Also of Interest...
04-237 Promoting myelination with gamma-secretase inhibitors
07-095 Role of extracellular matrix proteins Hevin and SPARC in Central Nervous System Synapse Formation
07-118 Small molecule drugs with TGFbeta signaling activity

Recently Viewed...
S07-363 Prokineticin 2 and Prokineticin Receptor 2 as a Target to Treat Epilepsy and Seizures